Peginesatide in Patients with Anemia Undergoing Hemodialysis
Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), administered monthly, was as effective as epoetin, administered 1 to 3 times per week, in maintaining hemoglobin levels in patients undergoing hemodialysis.
See the accompanying article on outcomes in CKD patients: http://www.nejm.org/doi/full/10.1056/NEJMoa1203166
See the accompanying editorial: http://www.nejm.org/doi/full/10.1056/NEJMe1215043
:
Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator
“Daily” Dialysis — Lessons from a Randomized, Controlled Trial
Testosterone deficiency is a cause of anemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Anemia Hemodialysis Source Type: research
More News: Anemia | Chronic Kidney Disease | Dialysis | Hemodialysis | Lessons | Urology & Nephrology